|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 加强流行病学中观察性研究报告质量(STROBE)声明:观察性研究报告规范显示文摘很多生物医学研究都是观察性的。但对这类研究的报告却通常不完整,从而限制了对其优缺点及普适性的评价。“加强流行病学中观察性研究报告质量(STROBE)”工作组针对一篇完整明确的观察性研究报告应包括的内容提供了一套建议。建议涵盖了流行病学研究的三种主要设计类型:队列设计、病例对照设计和横断面设计。2004年9月,我们召开了为期2天的研讨会,与会的方法学专家、研究人员和期刊编辑共同起草了一份观察性研究报告应纳入的条目清单草案。此后,又通过协调小组数次会议及与有关人员电子邮件讨论等对该草案进行了修改,纳入了经验性证据和方法学方面的意见。通过研讨会及之后反复的咨询和修订,我们制定出了一个包含22个条目的清单(STROBE声明),分为论文的题目、摘要、引言、方法、结果和讨论等部分。其中18个条目适用于所有三种主要的观察性研究设计,其余4个条目则专门用于队列、病例一对照或横断面设计。详细的解释和示范文件已另行发表,在《公共科学图书馆一医学》(PLoS Medicine)、《内科学年报》(Annalsof Internal Medicine)和《流行病学》(Epidemiology)的网站可以免费获得。我们希望STROBE声明能有助于改善观察性研究报告的质量。 | Erikvon Elm Douglas G Altman Matthias Egger Stuart J Pocock Peter C G tzsche Jan P Vandenbroucke 赵乐(译) 邹光勇(审) 杜怀东(审) | 2008 | 世界临床医学2008，2，1： | 12 |
| 2 | 基于一个大型随机试验预测稳定性心绞痛队列患者死亡、心肌梗死和卒中的危险评分显示文摘目的对需要抗心绞痛治疗并且左心室功能代偿症状稳定的心绞痛患者建立预测全因死亡、心肌梗死和导致致残性卒中的复合危险评分。设计大型多中心临床试验数据的多变量Cox回归分析。背景西欧、以色列、加拿大、澳大利亚和新西兰的心脏专科门诊患者。入选者7311例具有全部需要资料的患者被入选。主要结局的测量指标平均随访4.9年时间内所有原因的死亡、心肌梗死或者致残性卒中。结果1063例患者发生任何原因死亡或者持久性心肌梗死或者致残性卒中。这些复合终点的5年危险性在危险性最低的十分位患者为4%,而在危险性最高的十分位患者为35%。危险评分结合16项临床常规变量的降序排序是:年龄、左心室射血分数、吸烟、白细胞计数、糖尿病、随机血糖浓度、肌酐浓度、既往卒中病史、1周至少1次心绞痛发作、冠状动脉造影发现(如果能够获得)、降脂治疗、QT间期、收缩期血压≥150mmHg、抗心绞痛药物数量、陈旧性心肌梗死以及性别。把这个模型分别应用于任何原因所致的死亡、心肌梗死和卒中进行预测评估,所得的结果相似。危险评分似乎不能预测事件性质(39%的死亡、46%心肌梗死以及15%致残性卒中)或者冠状动脉造影或血管重建率(占29%的患者)。结论该危险评分对客观地决定稳定性心绞痛患者进一步治疗措施以减少重要预后事件发生是有帮助的。该危险评分同样可以用于将来的计划性试验。 | Tim C Clayton Stuart J Pocock Jacobus Lubsen Zoltán Vokó Bridget-Anne Kirwan Keith A A Fox Philip A Poole-Wilson | 2006 | 英国医学杂志中文版2006，9，1： | 2 |
| 3 | The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies显示文摘 | Erik von Elm Douglas G Altman Matthias Egger Stuart J Pocock Peter C G?tzsche Jan P Vandenbroucke | 2007 | The Lancet2007，，9596： | 1 |
| 4 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial显示文摘 | Gregg W Stone Bernhard Witzenbichler Giulio Guagliumi Jan Z Peruga Bruce R Brodie Dariusz Dudek Ran Kornowski Franz Hartmann Bernard J Gersh Stuart J Pocock George Dangas S Chiu Wong Martin Fahy Helen Parise Roxana Mehran | 2011 | The Lancet . 2011 (9784)2011，，9784： | 1 |
| 5 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial显示文摘 | Philip D Home Stuart J Pocock Henning Beck-Nielsen Paula S Curtis Ramon Gomis Markolf Hanefeld Nigel P Jones Michel Komajda John JV McMurray | 2009 | The Lancet2009，，9681： | 1 |
| 6 | Subgroup analysis and other (mis)uses of baseline data in clinical trials显示文摘 | Susan F Assmann Stuart J Pocock Laura E Enos Linda E Kasten | 2000 | The Lancet2000，，9209： | 1 |
| 7 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial显示文摘 | Gregg W Stone Bernhard Witzenbichler Giulio Guagliumi Jan Z Peruga Bruce R Brodie Dariusz Dudek Ran Kornowski Franz Hartmann Bernard J Gersh Stuart J Pocock George Dangas S Chiu Wong Martin Fahy Helen Parise Roxana Mehran | 2011 | The Lancet2011，，9784： | 1 |
| 8 | Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial显示文摘 | Gregg W Stone Bernhard Witzenbichler Giulio Guagliumi Jan Z Peruga Bruce R Brodie Dariusz Dudek Ran Kornowski Franz Hartmann Bernard J Gersh Stuart J Pocock George Dangas S Chiu Wong Martin Fahy Helen Parise Roxana Mehran | 2011 | The Lancet2011，，9784： | 1 |
| 9 | Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial显示文摘 | Roxana Mehran Alexandra J Lansky Bernhard Witzenbichler Giulio Guagliumi Jan Z Peruga Bruce R Brodie Dariusz Dudek Ran Kornowski Franz Hartmann Bernard J Gersh Stuart J Pocock S Chiu Wong Eugenia Nikolsky Louise Gambone Lynn Vandertie Helen Parise George | 2009 | The Lancet2009，，9696： | 1 |
| 10 | 研究方法学 如何解读临床试验报告中的统计图显示文摘一个统计图可能会胜过千言万语,但在医学研究中。 | Stuart J Pocock Thomas G Travison Lisa M Wruck 王淳秀(译) 单广良(校) | 2008 | 英国医学杂志中文版2008，11，4： | 0 |
| 11 | Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial显示文摘Introduction Nitrate-induced headache is common and may signify responsive cerebral vasculature.We assessed the relationship between nitrate headache and outcome in patients with acute stroke.Materials and methods Patients were those randomised to glyceryl trinitrate(GTN)versus no GTN in the efficacy of nitric oxide in stroke trial.Development of headache by end of treatment(day 7),and functional outcome(modified Rankin Scale,primary outcome)at day 90,were assessed.Analyses are adjusted for baseline prognostic factors and give OR and mean difference(MD)with 95%CI.Results In 4011 patients,headache was more common in GTN than control(360,18.0% vs 170,8.5%;p<0.001).Nitrate-related headache was associated with:younger age,female sex,higher diastolic blood pressure,non-total anterior circulation syndrome,milder stroke and absence of dysphasia(p<0.05).Nitrate headache was not associated with improved functional outcome(OR 0.90,95% CI 0.73 to 1.10,p=0.30)or death(day 90)(HR 0.64,95% CI 0.40 to 1.02,p=0.062),but reduced death or deterioration(day 7)(OR 0.45,95% CI 0.25 to 0.82),death in hospital(OR 0.44,95% CI 0.22 to 0.88)and improved activities of daily living(Barthel index,MD 3.7,95% CI 0.3 to 7.1)and cognition(telephone interview cognitive screen,MD 2.0,95% CI 0.7 to 3.3)(day 90).Non-nitrate headache was not associated with death,disability or cognition.Discussion and conclusion Development of a nitrate headache by day 7 after stroke may be associated with improved activities of daily living and cognitive impairment at day 90,which was not seen with non-nitrate headache. | Lucy Beishon Lisa J Woodhouse Daniel Bereczki Hanne K Christensen Ronan Collins John Gommans Christina Kruuse George Ntaios Serefnur Ozturk Stephen Phillips Stuart Pocock Szabolcs Szatmari Joanna Wardlaw Nikola Sprigg Philip M Bath | 2021 | Stroke & Vascular Neurology2021，6，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员